S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL
OncLive® On Air - Un pódcast de OncLive® On Air
Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.
